Transforming precision medicine through in-depth genomics.

Novel genomic technologies for deep insight into tumor biology, evolution, and treatment.

Led by a well-established team with advanced genome analysis, bioinformatics, and assay development expertise.

Check out our publications

Founders

Ignaty Leshchiner, PhD
Associate Professor in Computational Biomedicine at the Boston University School of Medicine. Ignaty is a leading academic in the field of cancer computational biology. Focused on applying new genomic technologies, computational analysis and AI methods unravelling biology behind tumor development, treatment evasion, and progression to metastasis.
Dimitri Livitz, PhD
As Head of Data Science and Genomics, Dimitri applies statistical and AI models to real-world cancer data to advance cancer therapies. Previously at the Broad Institute of Harvard and MIT, he studied cancer heterogeneity and treatment resistance, co-authoring high-profile publications in Nature, Nature Medicine, and Cell. He holds a PhD from Columbia University for his research in Bayesian experimental design, which has laid the foundation for his current work.
Paul Trukhanov
Experienced startup entrepreneur with expertise in biotechnology, healthcare, data-intensive software engineering, which resulted in two successful startup exits. Paul have previously build web-scale software systems and now Paul leads data analysis software development teams as a Software Architect in Machine Learning at Dana Farber Cancer Institute.
Elizaveta Leshchiner, PhD
Dr. Liza Leshchiner is focused on experimental and computational biology of cancer. She has strong expertise in technology and high-throughput assay development, including genomic and screening assays. She earned her Ph.D. from Harvard University and is leading a team of scientists at the Broad Institute of Harvard and MIT.
Andrew Jacobs, JD
As CEO Andy has a 40-year record of starting, managing and growing multitude of small and medium sized companies. He currently serves as president and a Board Member for companies in the area of computational services and data management for cancer patients and has been heavily involved in several non-profit enterprises.

Tumor cells release cell free DNA (cfDNA) into the bloodstream

Image 1: Tumor Cells and Vessel
Image 2: Blood Vessel Cross-section
Image 3: Test Tube Components

SmartRD is NoRD Bio’s an ultra high sensitivity multi-modal liquid biopsy

  • Ultra deep cell-free (cf) DNA sequencing and analysis
  • Unique epigenetic data (methylation and nucleosome)
  • Proprietary AI/ML computational platform

With SmartRD, NoRD Bio offers an innovative, efficient, and transformative solution for monitoring disease progression and identifying clinically druggable targets.

cfDNA Sequencing

In-depth cfDNA analysis for treatment efficacy assessment, clonal evolution and resistance dynamics for biomarker discovery, revealing signal from all lesions.

Nature Medicine 2019
Subclonal Reconstruction

Evolution and resistance analysis of disease reveals latent trends and information invisible from bulk analysis, increasing statistical power in small cohorts.

Nature Medicine 2023
Identify Early Drivers

Establish previously unknown early genetic progression of cancers with unobtainable premalignant tissue for early detection, interception and prognostication.

Nature Cancer 2024